LSTA Lisata Therapeutics, Inc. - Common Stock
$1,20
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 6, 2026
52 Haftlık Aralık
$1–$5
5% of range
Analist Derecelendirmesi
BUY
9 analysts
Fiyat Hedefi
$4
+233% upside
P/E (TTM)
-1.0
ROE
—
Net Kâr Marjı
—
Lisata Therapeutics, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Devamını oku
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.
== References ==
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
LSTA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$1.20
Piyasa Değeri
—
P/E (TTM)
-1.0
EPS (TTM)
$-1.91
Gelir (TTM)
$170.0K
Temettü Verimi
—
ROE
—
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$1 – $5
LSTA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$170.0K
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-1.91
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
—
2016-12-31
→
2023-12-31
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
LSTA
Akran Ortalaması
P/E (TTM)
-1.0
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
LSTA
Akran Ortalaması
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
LSTA
Akran Ortalaması
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
LSTA
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
-83.0%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
LSTA
Akran Ortalaması
LSTA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
9 analist
- Güçlü Al 2 22,2%
- Al 4 44,4%
- Tut 3 33,3%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
1 analist · 2026-07-19
Düşük
$4.00
Yüksek
$4.00
Medyan hedef
$4.00
+233,3%
Ortalama hedef
$4.00
+233,3%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.10%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Eylül 2025 | $-0.49 | $-0.55 | 0.06% |
| 30 Haziran 2025 | $-0.54 | $-0.66 | 0.12% |
| 31 Mart 2025 | $-0.55 | $-0.54 | -0.01% |
| 31 Aralık 2024 | $-0.55 | $-0.78 | 0.23% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| LSTA | — | -1.0 | -83.0% | — | — | — |
| INAB | $23M | -0.5 | — | — | -90.8% | — |
| OSRH | — | — | — | — | — | — |
| BIVI | — | — | — | — | — | — |
| LNAI | $513M | -2.7 | — | — | -586.4% | — |
| XCUR | $35M | -6.9 | — | — | -77.3% | — |
| MTVA | $19M | -1.1 | -44.6% | -2543.7% | -173.5% | — |
| VTGN | — | -0.3 | 161.1% | -5491.3% | -136.8% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · | · | · | · | · | $35M | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $31M | |
| R&D Expense | · | · | · | · | $18M | $9M | $11M | $8M | $16M | $17M | |
| SG&A Expense | $10M | $12M | $13M | $14M | $11M | $10M | $9M | $9M | $12M | $13M | |
| Operating Expenses | $18M | $23M | $26M | $58M | $29M | $19M | $20M | $17M | $28M | $30M | |
| Operating Income | $-18M | $-22M | $-26M | $-58M | $-29M | $-19M | $-20M | $-17M | $-28M | $-30M | |
| Interest Expense | · | · | · | · | · | · | $0 | $5.0K | $378.0K | $2M | |
| Other Non-op | $-145.0K | $-257.0K | $-186.0K | $-155.0K | $-75.0K | $0 | $740.0K | $824.0K | $273.0K | $23.9K | |
| Pretax Income | $-18M | $-21M | $-23M | $-57M | $-29M | $-19M | $-19M | $-16M | $-28M | $-31M | |
| Income Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-12M | $0 | |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | $-1.67 | $2.56 | $-4.99 | |
| EPS (Diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 | |
| Shares (Basic) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| Shares (Diluted) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| EBITDA | · | $-22M | $-26M | $-58M | · | $-19M | $-20M | $-17M | $-27M | $-30M |
Bilanço 30
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $16M | $23M | $32M | $25M | $17M | $14M | $10M | $29M | $7M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $26M | $0 | |
| Receivables | $0 | $900.0K | $0 | · | · | · | · | · | $234.5K | $138.8K | |
| Prepaid Expense | $2M | $2M | $3M | $3M | $1M | $758.0K | $815.0K | $1M | $1M | $2M | |
| Current Assets | $18M | $35M | $54M | $72M | $96M | $35M | $26M | $44M | $61M | $25M | |
| PP&E (Net) | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K | $57.0K | $100.0K | $165.0K | $257.0K | $705.4K | |
| PP&E (Gross) | $494.0K | $661.0K | $661.0K | $713.0K | $430.0K | $370.0K | $349.0K | $349.0K | $1M | $2M | |
| Accum. Depreciation | $476.0K | $589.0K | $486.0K | $417.0K | $368.0K | $313.0K | $249.0K | $184.0K | $832.0K | $1M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $7M | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $0 | · | · | · | · | $2M | |
| Other Non-current Assets | $23.0K | $160.0K | $332.0K | $528.0K | $764.0K | $614.0K | $1M | $309.0K | $2M | $2M | |
| Total Assets | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Accounts Payable | $1M | $1M | $2M | $3M | $2M | $1M | $1M | $762.0K | $1M | $2M | |
| Accrued Liabilities | $2M | $4M | $4M | $4M | $3M | $2M | $4M | $5M | $8M | $3M | |
| Short-term Debt | · | · | · | · | · | · | · | $0 | $159.0K | $563.8K | |
| Current Liabilities | $3M | $6M | $7M | $6M | $5M | $4M | $6M | $6M | $9M | $21M | |
| Capital Leases | $0 | $0 | $137.0K | $305.0K | $485.0K | $254.0K | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $1M | |
| Other Non-current Liabilities | $72.0K | $72.0K | $210.0K | $327.0K | $485.0K | $254.0K | $624.0K | $2M | $4M | $389.9K | |
| Total Liabilities | $3M | $6M | $7M | $7M | $5M | $4M | $7M | $7M | $13M | $30M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $6M | |
| Total Debt | · | · | · | · | · | · | · | $0 | $159.2K | $6M | |
| Common Stock | $9.0K | $8.0K | $8.0K | $8.0K | $4.0K | $19.0K | $11.0K | $10.0K | $9.0K | $8.2K | |
| Paid-in Capital | $580M | $578M | $577M | $575M | $546M | $459M | $439M | $436M | $433M | $410M | |
| Retained Earnings | $-565M | $-548M | $-528M | $-507M | $-453M | $-426M | $-417M | $-398M | $-382M | $-405M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $707.6K | |
| AOCI | $-37.0K | $-81.0K | $-42.0K | $-29.0K | $-70.0K | $-13.0K | $2.0K | $-32.0K | $-28.0K | $0 | |
| Stockholders' Equity | $15M | $30M | $48M | $67M | $92M | $32M | $21M | $38M | $51M | $5M | |
| Liabilities + Equity | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Shares Outstanding | 8,833,875 | 8,410,000 | 8,151,000 | 7,867,000 | 3,986,000 | 1,292,000 | 10,517,609 | 9,865,735 | 9,483,911 | 8,205,790 |
Nakit Akışı 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K | $100.0K | $100.0K | $200.0K | $400.0K | $500.0K | |
| Stock-based Comp | $1M | $2M | $2M | · | · | · | · | · | · | · | |
| Deferred Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-576.0K | $0 | |
| Amort. of Intangibles | $65.0K | $71.0K | $71.0K | $21.0K | · | · | · | · | · | $570.0K | |
| Other Non-cash | · | · | $3M | $35M | · | $10M | $379.0K | $-4M | $-44M | $8M | |
| Operating Cash Flow | $-16M | $-19M | $-20M | $-21M | $-22M | $-9M | $-19M | $-20M | $-21M | $-24M | |
| CapEx | $28.0K | $0 | $0 | $285.0K | $60.0K | $20.0K | $0 | $134.0K | $135.0K | $1M | |
| Investing Cash Flow | $15M | $13M | $10M | $29M | $-55M | $-7M | $21M | $-5M | $41M | $-3M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-6M | $-9M | |
| Stock Issued | $844.0K | $68.0K | $321.0K | $43.0K | $86M | $19M | · | · | · | · | |
| Net Stock Activity | · | $68.0K | $321.0K | $43.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $599.0K | $-206.0K | $385.0K | $-224.0K | $85M | $19M | $1M | $824.0K | $-932.0K | $21M | |
| Net Change in Cash | $-253.0K | $-6M | $-10M | $8M | $8M | $2M | $4M | $-24M | · | $-6M | |
| Taxes Paid | $6.0K | $6.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | $-20M | $-21M | · | $-9M | $-19M | $-20M | $-21M | $-27M | |
| Levered FCF | · | · | · | · | · | · | $-19M | $-20M | $-21M | $-28M |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -2240.9% | · | · | · | · | · | · | · | -88.8% | |
| Net Margin | · | -1998.5% | · | · | · | · | · | · | · | -94.4% | |
| Pretax Margin | · | -2078.3% | · | · | · | · | · | · | · | -94.0% | |
| EBITDA Margin | · | -2240.9% | · | · | · | · | · | · | · | -83.7% | |
| ROA | · | -44.6% | -32.6% | -63.8% | · | -25.8% | -54.0% | -29.9% | 39.3% | -57.9% | |
| ROE | · | -51.4% | -36.3% | -68.3% | · | -30.6% | -66.1% | -36.6% | 83.0% | -232.9% | |
| ROIC | · | -72.9% | -48.0% | -82.7% | · | -25.2% | -96.5% | -45.0% | -31.8% | -276.4% |
Likidite ve Solventlik 5
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · | 10.1 | 4.3 | 7.8 | 6.6 | 1.3 | |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · | 4.7 | 2.3 | 1.8 | 5.9 | 0.9 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.0 | 0.0 | 1.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -3397.4 | -73.0 | -16.9 |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.6 | |
| Receivables Turnover | · | 2.2 | · | · | · | · | · | · | · | 12.9 |
Büyüme Oranları 1
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170.0K | $1M | $0 | $0 | $33M | $33M | $33M | $33M | $33M | $35M | |
| Net Income TTM | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| Market Cap | · | $25M | $22M | $20M | · | $416M | $396M | $527M | $499M | $348M | |
| Enterprise Value | · | · | · | · | · | · | · | $517M | $444M | $340M | |
| P/E | -1.0 | -1.2 | -1.1 | -0.2 | -1.7 | -40.5 | · | · | 20.6 | -8.5 | |
| P/S | · | 25.1 | · | · | · | 12.6 | 12.0 | 15.9 | 15.1 | 9.9 | |
| P/B | · | 0.8 | 0.5 | 0.3 | · | 12.8 | 19.0 | 14.0 | 9.9 | 71.3 | |
| P / Tangible Book | 1.1 | 0.9 | 0.5 | 0.3 | 8.2 | 12.8 | · | · | · | · | |
| P / Cash Flow | · | -1.3 | -1.1 | -0.9 | · | -47.1 | -21.0 | -26.4 | -23.9 | -14.7 | |
| P / FCF | · | · | -1.1 | -0.9 | · | -47.0 | -21.0 | -26.2 | -23.8 | -13.1 | |
| EV / EBITDA | · | · | · | · | · | · | · | -30.8 | -16.3 | -11.5 | |
| EV / FCF | · | · | · | · | · | · | · | -25.7 | -21.2 | -12.8 | |
| EV / Revenue | · | · | · | · | · | · | · | 15.6 | 13.5 | 9.6 | |
| Earnings Yield | -102.7% | -80.5% | -94.5% | -413.8% | -59.1% | -2.5% | · | · | 4.9% | -11.8% |
Gelir Tablosu 13
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $70.0K | $0 | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $3M | $4M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | |
| Operating Expenses | $4M | $5M | $3M | $4M | $5M | $6M | $6M | $5M | $6M | $7M | $6M | $6M | $7M | $7M | $7M | $38M | |
| Operating Income | $-4M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-6M | $-7M | $-6M | $-6M | $-7M | $-7M | $-7M | $-38M | |
| Other Non-op | $984.0K | $-54.0K | $-15.0K | $-18.0K | $-7.0K | $-105.0K | $-11.0K | $-45.0K | $-14.0K | $-187.0K | $-12.0K | $-11.0K | $-150.0K | $-13.0K | $-7.0K | $0 | |
| Pretax Income | $-3M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-5M | $-6M | $-5M | $-5M | $-6M | $-6M | $-6M | $-37M | |
| Income Tax | $0 | $-387.0K | $0 | $0 | $0 | $-962.0K | $0 | $0 | $0 | $-798.0K | $0 | $0 | $-2M | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-3M | $-4M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-4M | $-6M | $-6M | $-37M | |
| EPS (Basic) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| EPS (Diluted) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| Shares (Basic) | 9,106,000 | 9,006,000 | -17,258,000 | 8,738,000 | 8,605,000 | 8,602,000 | -16,594,000 | 8,321,000 | 8,308,000 | 8,294,000 | -16,076,000 | 8,141,000 | 8,021,000 | 7,987,000 | -7,639,000 | 4,747,000 | |
| Shares (Diluted) | 9,106,000 | 9,006,000 | -17,258,000 | 8,738,000 | 8,605,000 | 8,602,000 | -16,594,000 | 8,321,000 | 8,308,000 | 8,294,000 | -16,076,000 | 8,141,000 | 8,021,000 | 7,987,000 | -7,639,000 | 4,747,000 | |
| EBITDA | $-4M | $-5M | · | $-4M | $-5M | $-6M | · | $-5M | $-6M | $-7M | · | $-6M | $-7M | $-7M | · | $-38M |
Bilanço 24
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $16M | $19M | $17M | $20M | $16M | $20M | $28M | $22M | $23M | $32M | $24M | $28M | $32M | $31M | |
| Receivables | · | · | $0 | · | · | · | $900.0K | · | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $570.0K | $960.0K | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $3M | $3M | $4M | $4M | $3M | $2M | |
| Current Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $42M | $48M | $54M | $57M | $61M | $65M | $72M | $77M | |
| PP&E (Net) | $14.0K | $16.0K | $18.0K | $22.0K | $48.0K | $74.0K | $72.0K | $96.0K | $119.0K | $146.0K | $175.0K | $204.0K | $233.0K | $262.0K | $296.0K | $299.0K | |
| PP&E (Gross) | $494.0K | $494.0K | $494.0K | $494.0K | $566.0K | $689.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $713.0K | · | |
| Accum. Depreciation | $480.0K | $478.0K | $476.0K | $472.0K | $518.0K | $615.0K | $589.0K | $565.0K | $542.0K | $515.0K | $486.0K | $457.0K | $428.0K | $399.0K | $417.0K | · | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $352.0K | |
| Other Non-current Assets | $0 | $23.0K | $23.0K | $23.0K | $70.0K | $116.0K | $160.0K | $201.0K | $246.0K | $290.0K | $332.0K | $371.0K | $410.0K | $449.0K | $528.0K | $588.0K | |
| Total Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Accounts Payable | $836.0K | $510.0K | $1M | $619.0K | $782.0K | $602.0K | $1M | $556.0K | $728.0K | $1M | $2M | $1M | $775.0K | $1M | $3M | $974.0K | |
| Accrued Liabilities | $2M | $3M | $2M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $4M | $5M | $7M | $5M | $4M | $5M | $6M | $6M | |
| Capital Leases | · | · | $0 | · | · | · | $0 | $0 | $47.0K | $92.0K | $137.0K | $181.0K | $223.0K | $265.0K | $305.0K | $345.0K | |
| Other Non-current Liabilities | $50.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $119.0K | $164.0K | $210.0K | $253.0K | $295.0K | $337.0K | $327.0K | $367.0K | |
| Total Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $5M | $5M | $7M | $5M | $5M | $6M | $7M | $7M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | |
| Paid-in Capital | $581M | $581M | $580M | $580M | $579M | $579M | $578M | $578M | $578M | $577M | $577M | $576M | $576M | $575M | $575M | $574M | |
| Retained Earnings | $-572M | $-569M | $-565M | $-562M | $-557M | $-553M | $-548M | $-543M | $-539M | $-533M | $-528M | $-523M | $-517M | $-513M | $-507M | $-501M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | |
| AOCI | $-17.0K | $-21.0K | $-37.0K | $-42.0K | $-50.0K | $-78.0K | $-81.0K | $-32.0K | $-77.0K | $-104.0K | $-42.0K | $-100.0K | $-50.0K | $-52.0K | $-29.0K | $-90.0K | |
| Stockholders' Equity | $8M | $11M | $15M | $17M | $21M | $25M | $30M | $34M | $38M | $43M | $48M | $53M | $58M | $61M | $67M | $72M | |
| Liabilities + Equity | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Shares Outstanding | 9,119,004 | 9,107,291 | 8,833,875 | 8,755,948 | 8,626,464 | 8,620,162 | 8,408,844 | 8,319,600 | 8,321,061 | 8,307,433 | 8,149,897 | 8,139,449 | 8,132,357 | 7,998,342 | 7,866,061 | 7,862,602 |
Nakit Akışı 11
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.0K | $2.0K | $15.0K | $44.0K | $44.0K | $43.0K | $41.0K | $42.0K | $45.0K | $46.0K | $47.0K | $47.0K | $47.0K | $48.0K | · | $8.0K | |
| Stock-based Comp | $214.0K | $364.0K | · | · | $239.0K | $530.0K | · | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $0 | $0 | $12.0K | $18.0K | $18.0K | $17.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $18.0K | $18.0K | $18.0K | $18.0K | · | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-3M | $-4M | $-5M | $-5M | $-3M | $-5M | $-7M | $-4M | $-4M | $-4M | $-8M | $-6M | $-4M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $28.0K | $0 | $0 | $0 | $0 | · | $0 | · | · | $26.0K | $24.0K | |
| Investing Cash Flow | $0 | $0 | $0 | $5M | $505.0K | $9M | $1M | $-6M | $12M | $6M | $-6M | $12M | $-725.0K | $4M | $7M | $2M | |
| Stock Issued | $29.0K | $0 | $205.0K | $353.0K | $74.0K | $212.0K | $36.0K | $0 | $32.0K | $0 | $24.0K | $0 | · | · | $14.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $212.0K | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $29.0K | $181.0K | $205.0K | $353.0K | $64.0K | $-23.0K | $-96.0K | $0 | $32.0K | $-142.0K | $24.0K | $-6.0K | $452.0K | $-85.0K | $14.0K | $-99.0K | |
| Net Change in Cash | $-3M | $-3M | $-3M | $2M | $-3M | $4M | $-3M | $-9M | $6M | $-788.0K | $-10M | $9M | $-4M | $-4M | $676.0K | $-2M | |
| Free Cash Flow | · | $-3M | · | · | · | $-5M | · | · | · | · | · | · | · | · | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -16.2% | -20.9% | · | -14.2% | -13.8% | -12.2% | · | -10.2% | -9.6% | -9.4% | · | -7.7% | -5.4% | -7.8% | · | -41.3% | |
| ROE | -20.0% | -24.8% | · | -16.6% | -15.7% | -13.8% | · | -11.4% | -10.5% | -10.4% | · | -8.4% | -5.7% | -8.3% | · | -43.8% | |
| ROIC | -48.4% | -41.6% | · | -25.4% | -23.2% | -19.2% | · | -15.8% | -14.4% | -13.4% | · | -11.3% | -7.5% | -11.2% | · | -52.4% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | · | 4.7 | 5.8 | 7.5 | · | 8.0 | 9.4 | 8.9 | · | 11.2 | 14.1 | 12.4 | · | 12.1 | |
| Quick Ratio | 3.5 | 3.9 | · | 4.2 | 3.9 | 5.3 | · | 4.2 | 6.3 | 4.1 | · | 6.3 | 5.4 | 5.3 | · | 4.9 |
Verimlilik 1
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $70.0K | $70.0K | · | $70.0K | $70.0K | $0 | · | $0 | $0 | $0 | · | $0 | · | · | · | · | |
| Net Income TTM | $-16M | $-18M | · | $-19M | $-19M | $-20M | · | $-21M | $-20M | $-21M | · | $-53M | $-54M | $-54M | · | $-55M | |
| Market Cap | $31M | $46M | · | $23M | $25M | $20M | · | $25M | $29M | $26M | · | $17M | $30M | $26M | · | $36M | |
| P/E | -1.8 | -2.4 | · | -1.2 | -1.3 | -1.0 | · | -1.2 | -1.4 | -1.2 | · | -0.2 | -0.3 | -0.3 | · | -0.4 | |
| P/S | 442.9 | 651.8 | · | 327.7 | 357.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.8 | 4.2 | · | 1.3 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Tangible Book | 4.0 | 4.3 | · | 1.4 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Cash Flow | · | -14.8 | · | · | · | -3.8 | · | · | · | -3.7 | · | · | · | -3.2 | · | · | |
| P / FCF | · | -14.8 | · | · | · | -3.7 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -54.4% | -41.5% | · | -82.8% | -79.0% | -102.1% | · | -83.3% | -69.5% | -82.4% | · | -457.9% | -291.6% | -348.9% | · | -265.9% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $170.0K | $1M | $0 | $0 | — |
| Faaliyet Kâr Marjı % | — | -2240.9% | — | — | — |
| Net Gelir | $-17M | $-20M | $-21M | $-54M | $-27M |
| Seyreltilmiş Hisse Başı Kâr | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | — | 6.2 | 8.2 | 11.3 | — |
| Cari Oran | — | 3.0 | 3.4 | 5.0 | — |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | — | — | $-20M | $-21M | — |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 34 dosya · $3.5M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 6 (-5 önceki Ç'ye göre) | 5 (+1 önceki Ç'ye göre) | 7 (+2 önceki Ç'ye göre) | 5 (+3 önceki Ç'ye göre) | +329K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $948.046 | 278.837 | 27,01% | Hisse senetleri |
| Yakira Capital Management, Inc. | $471.107 | 138.561 | 13,42% | Hisse senetleri |
| CSS LLC/IL | $375.435 | 110.422 | 10,70% | Hisse senetleri |
| DELTEC ASSET MANAGEMENT LLC | $282.870 | 83.197 | 8,06% | Hisse senetleri |
| Rangeley Capital, LLC | $275.400 | 81.000 | 7,85% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $195.517 | 57.490 | 5,57% | Hisse senetleri |
| BlackRock, Inc. | $186.514 | 54.857 | 5,31% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $166.478 | 48.964 | 4,74% | Hisse senetleri |
| GTS SECURITIES LLC | $102.680 | 30.200 | 2,93% | Hisse senetleri |
| STATE STREET CORP | $86.183 | 25.348 | 2,46% | Hisse senetleri |
| VANGUARD GROUP INC | $56.321 | 30.280 | 1,60% | Hisse senetleri |
| CITADEL ADVISORS LLC | $52.839 | 15.541 | 1,51% | Hisse senetleri |
| NORTHERN TRUST CORP | $52.816 | 15.534 | 1,50% | Hisse senetleri |
| JBF Capital, Inc. | $48.780 | 14.347 | 1,39% | Hisse senetleri |
| JANE STREET GROUP, LLC | $47.291 | 13.909 | 1,35% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $35.200 | 10.353 | 1,00% | Hisse senetleri |
| HighTower Advisors, LLC | $34.143 | 10.042 | 0,97% | Hisse senetleri |
| SOL Capital Management CO | $29.342 | 12.175 | 0,84% | Hisse senetleri |
| COOK WEALTH MANAGEMENT GROUP LLC | $29.342 | 12.175 | 0,84% | Hisse senetleri |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $16.800 | 5.000 | 0,48% | Hisse senetleri |
| Founders Capital Management | $5.668 | 1.667 | 0,16% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $3.512 | 1.033 | 0,10% | Hisse senetleri |
| Connective Capital Management, LLC | $3.454 | 1.016 | 0,10% | Hisse senetleri |
| Tower Research Capital LLC (TRC) | $2.468 | 726 | 0,07% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $680 | 200 | 0,02% | Hisse senetleri |
| Caitong International Asset Management Co., Ltd | $306 | 90 | 0,01% | Hisse senetleri |
| BARCLAYS PLC | $238 | 70 | 0,01% | Hisse senetleri |
| MORGAN STANLEY | $228 | 67 | 0,01% | Hisse senetleri |
| Virtu Financial LLC | $200 | 58.782 | 0,01% | Hisse senetleri |
| Cerity Partners LLC | $27 | 8 | 0,00% | Hisse senetleri |
| SBI Securities Co., Ltd. | $24 | 7 | 0,00% | Hisse senetleri |
| Cheviot Value Management, LLC | $10 | 3 | 0,00% | Hisse senetleri |
| Fortitude Family Office, LLC | $3 | 1 | 0,00% | Hisse senetleri |
| ROYAL BANK OF CANADA | $0 | 39 | 0,00% | Hisse senetleri |
Şirket yöneticileri 43 içeriden öğrenenler · 24 yöneticiler · 13 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Joseph Talamo | SVP and CFO | 20 Haziran 2018 F | 35.210 | 0 | 0 | $0 |
| Robert S Vaters | President & CFO | 12 Ağustos 2015 P | 228.750 | 0 | 0 | $0 |
| Robert Dickey IV | Chief Financial Officer | 31 Aralık 2014 A | 12.066 | 0 | 0 | $0 |
| Larry Alan May | Chief Financial Officer | 02 Ocak 2013 A | 64.618 | 0 | 0 | $0 |
| Hans Keirstead | President of the Issuer's NeoStem Oncology, LLC subsidiary. | 09 Mayıs 2014 A | — | 0 | 0 | $0 |
| Ian Zhang | President and Managing Director, NeoStem (China), Inc. | 04 Nisan 2011 A | 10.000 | 0 | 0 | $0 |
| Mark Weinreb | President | 21 Mayıs 2009 A | 66.923 | 0 | 0 | $0 |
| Robert Joseph Aholt JR | Chief Operating Officer | 03 Ekim 2005 A | 4.369.317 | 0 | 0 | $0 |
| Douglas W Losordo | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | 20 Haziran 2018 F | 93.982 | 0 | 0 | $0 |
| Robin L Smith | Executive Chair of the Board | 02 Haziran 2015 A | 347.285 | 0 | 0 | $0 |
| Catherine M Vaczy | General Counsel | 13 Nisan 2015 A | 71.234 | 0 | 0 | $0 |
| Stephen W Potter | Executive Vice President | 31 Aralık 2014 A | 14.016 | 0 | 0 | $0 |
| Robert Dillman | Vice President, Oncology of the Issuer. The Reporting Person also serves as Chief Medical Officer of the Issuer's NeoStem Oncolo | 09 Mayıs 2014 A | — | 0 | 0 | $0 |
| Martin E Schmieg | Vice President - Corporate Dev | 25 Haziran 2012 A | — | 0 | 0 | $0 |
| Jonathan Sackner-Bernstein | VP Clinical Dev & Reg Affairs | 02 Nisan 2012 A | — | 0 | 0 | $0 |
| Jason Kolbert | VP of Strategic Business Development | 04 Ocak 2012 A | 8.000 | 0 | 0 | $0 |
| Mingsheng Shi | Chairman of the Board of Directors of Suzhou Erye Pharmaceutical Company Ltd., an entity 51%-owned by the Company. | 04 Ocak 2012 A | 3.650.770 | 0 | 0 | $0 |
| Alan G Harris | Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs | 04 Nisan 2011 A | — | 0 | 0 | $0 |
| Anthony Salerno | Vice President, Operations and Academic Affairs Exhibit List Exhibit 24 - Power of Attorney | 09 Haziran 2010 A | — | 0 | 0 | $0 |
| Jian M Zhang | Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidi | 09 Haziran 2010 A | 3.650.770 | 0 | 0 | $0 |
| Christopher C Duignan | Vice President, Finance | 30 Kasım 2009 A | — | 0 | 0 | $0 |
| Lepore Teresa Linn Samuels | VP of Sales and Marketing | 29 Ekim 2009 A | — | 0 | 0 | $0 |
| Renee Cohen | VP of Oper. & Corp. Strategy | 27 Şubat 2008 A | 31.000 | 0 | 0 | $0 |
| Wayne A Marasco | Senior Scientific Advisor | 02 Haziran 2006 A | 1.436.713 | 0 | 0 | $0 |
| Steven M Klosk | Yönetim kurulu üyesi | 09 Ocak 2026 A | 95.815 | 0 | 0 | $0 |
| MYERS STEVEN S | Yönetim kurulu üyesi | 10 Ocak 2022 A | 212.269 | 0 | 0 | $0 |
| Eric Wei | Yönetim kurulu üyesi | 07 Şubat 2017 S | 172.223 | 0 | 0 | $0 |
| Richard J Berman | Yönetim kurulu üyesi | 09 Ocak 2017 A | 7.177 | 0 | 0 | $0 |
| Andrew L Pecora | Yönetim kurulu üyesi | 22 Haziran 2016 A | 393.784 | 0 | 0 | $0 |
| Drew Bernstein | Yönetim kurulu üyesi | 02 Haziran 2015 A | 10.000 | 0 | 0 | $0 |
| Martyn D Greenacre | Yönetim kurulu üyesi | 02 Haziran 2015 A | 88.531 | 0 | 0 | $0 |
| Edward Geehr | Yönetim kurulu üyesi | 29 Haziran 2012 A | — | 0 | 0 | $0 |
| Joseph Zuckerman | Yönetim kurulu üyesi | 21 Mayıs 2009 A | 41.260 | 0 | 0 | $0 |
| RimAsia Capital Partners Manager, Ltd. | 10% sahip | 17 Eylül 2012 S | 105.306 | 0 | 0 | $0 |
| Gregory B Brown | — | 09 Ocak 2026 A | 95.659 | 0 | 0 | $0 |
| David J Mazzo | — | 09 Ocak 2026 A | 311.890 | 0 | 0 | $0 |
| Mohammad Azab | — | 09 Ocak 2026 A | 104.925 | 0 | 0 | $0 |
| Heidi Henson | — | 09 Ocak 2026 A | 85.725 | 0 | 0 | $0 |
| Erkki Ruoslahti | — | 09 Ocak 2023 A | 20.000 | 0 | 0 | $0 |
| Peter G Traber | — | 10 Ocak 2022 A | 149.190 | 0 | 0 | $0 |
| Anne Clem Whitaker | — | 01 Kasım 2020 A | 79.470 | 0 | 0 | $0 |
| Robert A Preti | — | 18 Mayıs 2017 F | 33.786 | 0 | 0 | $0 |
| Aholt Jr Family Trust | — | 05 Haziran 2006 S | 12.352.227 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 20 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| RimAsia Capital Partners, L.P., RimAsia Capital Partners GP, L.P., RimAsia Capital Partners GP, Ltd., Eric H.C. Wei ×8 başvurular | 20 Mayıs 2010 | — | İlk başvuru | — | SEC |
| Robin L. Smith | 10 Eylül 2009 | — | İlk başvuru | Pasif yatırım | SEC |
| Catherine M. Vaczy | 10 Eylül 2009 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 16 Kasım 2007 | — | İlk başvuru | — | SEC |
| Açıklanmayan raporlama kişisi | 30 Ekim 2007 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 20 Şubat 2007 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 05 Ocak 2007 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 15 Aralık 2006 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 29 Haziran 2006 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 29 Haziran 2006 | — | İlk başvuru | Pasif yatırım | SEC |
| Mark Weinreb | 29 Haziran 2006 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 28 Haziran 2006 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 08 Aralık 2005 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 31 Ağustos 2005 | — | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 04 Ağustos 2005 | — | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 4 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 80.444 SH | 08 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 191.371 SH | 08 Ağustos 2026 | Günlük |
| DFSU · Dimensional ETF Trust | 0,00% | 100 NS | 30 Nisan 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 8 NS | 30 Nisan 2026 | N-PORT |